Assertio Holdings Inc
ASRT0.713USD
+0.001+0.08%
Market hours （ET）Quotes delayed by 15 min
68.30MMarket Cap
LossP/E TTM
More Details of Assertio Holdings Inc Company
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
Company Info
Ticker SymbolASRT
Company nameAssertio Holdings Inc
IPO dateFeb 12, 1997
CEOMr. Brendan P. O'Grady
Number of employees58
Security typeOrdinary Share
Fiscal year-endFeb 12
Address100 S. Saunders Road
CityLAKE FOREST
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code60045
Phone12244197106
Websitehttps://www.assertiotx.com/
Ticker SymbolASRT
IPO dateFeb 12, 1997
CEOMr. Brendan P. O'Grady
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Ajay Patel
Mr. Ajay Patel
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
196.85K
+12.05%
Mr. Paul Schwichtenberg
Mr. Paul Schwichtenberg
Executive Vice President, Chief Transformation Officer
Executive Vice President, Chief Transformation Officer
167.52K
+14.47%
Mr. Sam Schlessinger
Mr. Sam Schlessinger
Executive Vice President, General Counsel
Executive Vice President, General Counsel
156.13K
+17.33%
Mr. Brendan P. O'Grady
Mr. Brendan P. O'Grady
Chief Executive Officer, Director
Chief Executive Officer, Director
128.96K
+1001.61%
Mr. David Matthew Stark
Mr. David Matthew Stark
Independent Director
Independent Director
107.50K
+100.00%
Mr. William T. Mckee
Mr. William T. Mckee
Independent Director
Independent Director
97.28K
+123.48%
Mr. Mark L Reisenauer
Mr. Mark L Reisenauer
Independent Director
Independent Director
53.75K
--
Ms. Heather L. Mason
Ms. Heather L. Mason
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Sigurd C. (Sig) Kirk
Mr. Sigurd C. (Sig) Kirk
Independent Director
Independent Director
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Ajay Patel
Mr. Ajay Patel
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
196.85K
+12.05%
Mr. Paul Schwichtenberg
Mr. Paul Schwichtenberg
Executive Vice President, Chief Transformation Officer
Executive Vice President, Chief Transformation Officer
167.52K
+14.47%
Mr. Sam Schlessinger
Mr. Sam Schlessinger
Executive Vice President, General Counsel
Executive Vice President, General Counsel
156.13K
+17.33%
Mr. Brendan P. O'Grady
Mr. Brendan P. O'Grady
Chief Executive Officer, Director
Chief Executive Officer, Director
128.96K
+1001.61%
Mr. David Matthew Stark
Mr. David Matthew Stark
Independent Director
Independent Director
107.50K
+100.00%
Mr. William T. Mckee
Mr. William T. Mckee
Independent Director
Independent Director
97.28K
+123.48%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
ROLVEDON
13.12M
49.54%
INDOCIN products
5.54M
20.93%
other
3.56M
13.44%
Sympazan
2.18M
8.23%
SPRIX Nasal Spray
1.59M
6.00%
Royalties and milestone revenue
494.00K
1.86%
By RegionUSD
Name
Revenue
Proportion
United States
26.49M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
ROLVEDON
13.12M
49.54%
INDOCIN products
5.54M
20.93%
other
3.56M
13.44%
Sympazan
2.18M
8.23%
SPRIX Nasal Spray
1.59M
6.00%
Royalties and milestone revenue
494.00K
1.86%
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Nantahala Capital Management, LLC
8.81%
The Vanguard Group, Inc.
4.58%
Renaissance Technologies LLC
2.82%
BlackRock Institutional Trust Company, N.A.
1.45%
Two Sigma Investments, LP
1.28%
Other
81.06%
Shareholders
Shareholders
Proportion
Nantahala Capital Management, LLC
8.81%
The Vanguard Group, Inc.
4.58%
Renaissance Technologies LLC
2.82%
BlackRock Institutional Trust Company, N.A.
1.45%
Two Sigma Investments, LP
1.28%
Other
81.06%
Shareholder Types
Shareholders
Proportion
Hedge Fund
13.93%
Investment Advisor
9.29%
Investment Advisor/Hedge Fund
3.63%
Individual Investor
2.63%
Research Firm
0.15%
Other
70.37%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
311
28.39M
29.65%
-30.82M
2025Q1
337
28.16M
29.40%
-32.55M
2024Q4
339
31.00M
32.47%
-30.41M
2024Q3
330
33.06M
34.86%
-33.72M
2024Q2
326
40.98M
43.17%
-33.17M
2024Q1
316
48.96M
52.78%
-20.37M
2023Q4
308
49.49M
53.68%
-10.26M
2023Q3
295
49.25M
53.86%
+8.83M
2023Q2
258
36.71M
65.25%
+1.46M
2023Q1
203
27.95M
50.57%
+2.57M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Nantahala Capital Management, LLC
8.44M
8.81%
+291.43K
+3.58%
Mar 31, 2025
The Vanguard Group, Inc.
4.38M
4.58%
--
--
Mar 31, 2025
Renaissance Technologies LLC
2.70M
2.82%
-289.05K
-9.66%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.39M
1.45%
-13.17K
-0.94%
Mar 31, 2025
Two Sigma Investments, LP
1.23M
1.28%
-401.09K
-24.66%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.11M
1.16%
+11.78K
+1.08%
Mar 31, 2025
Millennium Management LLC
784.58K
0.82%
-316.70K
-28.76%
Mar 31, 2025
Polen Capital Management, LLC
424.06K
0.44%
-227.56K
-34.92%
Nov 30, 2024
AQR Capital Management, LLC
636.77K
0.66%
-265.80K
-29.45%
Mar 31, 2025
Peisert (Daniel A)
607.46K
0.63%
--
--
Mar 13, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Franklin US Small Cap Multifactor Index ETF
0%
ALPS Barron's 400 ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
Avantis Responsible US Equity ETF
0%
Global X Russell 2000 ETF
0%
Royce Quant Small-Cap Quality Value ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Avantis US Small Cap Equity ETF
0%
View more
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Franklin US Small Cap Multifactor Index ETF
Proportion0%
ALPS Barron's 400 ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Avantis Responsible US Equity ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Royce Quant Small-Cap Quality Value ETF
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 17, 2021
Merger
4<1
May 17, 2021
Merger
4<1
May 17, 2021
Merger
4<1
May 17, 2021
Merger
4<1
Date
Type
Ratio
May 17, 2021
Merger
4<1
May 17, 2021
Merger
4<1
May 17, 2021
Merger
4<1
May 17, 2021
Merger
4<1
